Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mentor Worldwide, LLC
ClinicalTrials.gov Identifier:
NCT00753922
First received: September 15, 2008
Last updated: March 21, 2014
Last verified: March 2014

September 15, 2008
March 21, 2014
September 2000
June 2012   (final data collection date for primary outcome measure)
  • 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.
  • Overall Mean Change in Circumferential Chest Size [ Time Frame: Change from baseline to 10 years post-baseline ] [ Designated as safety issue: No ]
    Change in Chest Size was calculated by subtracting the chest circumference prior to surgery from the chest circumference measured at the end of the study
  • 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture [ Time Frame: 10 Years ] [ Designated as safety issue: Yes ]
    Baker III was identified as "firm with visible distortion" and Baker IV was identified as "obvious spherical distortion". Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.
  • 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection [ Time Frame: 10 Years ] [ Designated as safety issue: Yes ]
    Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.
  • 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation With or Without Replacement [ Time Frame: 10 Years ] [ Designated as safety issue: Yes ]
    Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.
  • Effectiveness will be determined by the changes in chest circumference and bra and cup size. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Safety will be determined by the incidence, severity, method of resolution, and duration for all adverse events on a per implant and a per patient basis. [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00753922 on ClinicalTrials.gov Archive Site
Not Provided
Effectiveness will also be determined by changes in Quality of Life questionnaire results. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses
Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

The Core Gel Study is designed to demonstrate safety and effectiveness of Mentor's Round Low-Bleed Silicone Gel-filled Mammary Prostheses in women who are undergoing primary augmentation, primary reconstruction, or revision. Safety information on the rate of capsular contracture, rupture, and infection will be collected, and used to help determine device safety.

Approximately 1000 patients at centers across the United States will be enrolled in this research study. These patients will be implanted with silicone breast prostheses and monitored for 10 years to collect information on risks associated with the implant surgery as well as changes in the way these patients feel about themselves.

Silicone gel-filled breast implants were introduced in the early sixties and were in wide-scale distribution by the time the Medical Device Amendments to the Food Drug and Cosmetic Act was passed in 1976. In 1983, gel-filled breast implants were designated as Class III devices requiring premarket approval. In May 1990, the Food and Drug Administration (FDA) published a proposed request (515(b)) for Premarket Approval Applications (PMA) and in April 1991 published the final request. This final publication put manufacturers of gel-filled breast implants on notice that for continued marketing of gel-filled breast implants, a PMA was due to FDA in 90 days from the final publication date.

A premarket approval (PMA) for the Mentor gel-filled breast implants was filed with the FDA in July 1991. At the FDA General and Plastic Surgery Advisory Committee meeting in November 1991, the committee recommended the submission of additional information to establish the safety and effectiveness of gel-filled breast implants.

In January 1992, the FDA Commissioner announced a voluntary moratorium of the sale of gel-filled breast implants to allow the advisory panel time to assess additional information. In April 1992, the moratorium was lifted but only for reconstruction and revision patients. Every patient implanted had to be part of an adjunct study, and had to be offered participation in a registry of gel-filled breast implant patients. In order to be implanted with gel-filled implants for augmentation, women had to be enrolled in a core clinical study.

The objective of this study is to determine the safety and effectiveness of the smooth and textured surface Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses in women who are undergoing primary breast augmentation, primary breast reconstruction or revision.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Breast Reconstruction
  • Breast Augmentation
  • Breast Revision
Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
  • Primary Augmentation
    The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
    Intervention: Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
  • Primary Reconstruction

    The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.

    Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry.

    Intervention: Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
  • Revison Augmentation
    Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
    Intervention: Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
  • Revision Reconstruction
    Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
    Intervention: Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1008
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is Genetic female and at least 18 years old
  • A candidate for:
  • Primary breast augmentation (for post-lactational mammary involution or general breast enlargement)
  • Primary breast reconstruction (for cancer, trauma, surgical loss of breast or congenital deformity)
  • Revision surgery (previous augmentation or reconstruction with silicone-filled or saline-filled implants)
  • Signs the Informed Consent
  • Agrees to follow the procedures for explant analysis
  • Agrees to comply with follow-up procedures, including returning for all follow-up visits

Exclusion Criteria:

  • Patient is pregnant
  • Has nursed a child within three months of study enrollment
  • Been implanted with any silicone implant other than breast implants (e.g. silicone artificial joints or facial implants)
  • Confirmed diagnosis of the following rheumatic diseases or syndromes: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infections arthritis, spondylarthropathies, any other inflammatory arthritis, osteoarthritis, fibromyalgia, or chronic fatigue syndrome
  • Currently has a condition that could compromise or complicate wound healing (except reconstruction patients)
  • Patient in Augmentation cohort and has diagnosis of active cancer of any type
  • Infection or abscess anywhere in the body
  • Demonstrates tissue characteristics which are clinically incompatible with implant (e.g. tissue damage resulting from radiation, inadequate tissue, or compromised vascularity)
  • Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk
  • Anatomic or physiologic abnormality which could lead to significant postoperative adverse events
  • Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure
  • Premalignant breast disease without a subcutaneous mastectomy
  • Untreated or inappropriately treated breast malignancy, without mastectomy
  • Implanted metal or metal devices, history of claustrophobia or other condition that would make a MRI scan prohibitive
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00753922
10-009-0799-01
No
Mentor Worldwide, LLC
Mentor Worldwide, LLC
Not Provided
Not Provided
Mentor Worldwide, LLC
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP